Stream Link: https://event.arraylive.com/app/login/14db39b8-b35e-4bf9-8f05-6039f45eaa6b
Program Description
Though targeted therapies such as Bruton tyrosine kinase (BTK) and BCL-2 inhibitors have improved outcomes in chronic lymphocytic leukemia (CLL), challenges remain. Real-world data indicate high rates of discontinuation due to BTK inhibitor resistance or intolerance due to treatment-related adverse effects. These treatment effects limit medication adherence, which contributes to higher health care utilization costs. This virtual symposium will review the current treatment approaches for CLL, highlighting new dosing strategies, recent updates in treatment guidelines, and the managed care pharmacist's perspective on operational and financial challenges to optimizing coordination of care. Panelists will discuss continuous- and fixed-duration treatment regimens, with a focus on how incorporating new treatment strategies into CLL care pathways may alleviate financial burden for patients and the health care system.
Target audience: Managed care pharmacists and oncology pharmacists
Type of activity: Application
Release date: November 19, 2024
Expiration date: January 19, 2025
Time to complete activity: 1.5 hours
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Investigate challenges in current treatment approaches and emerging trends in chronic lymphocytic leukemia (CLL).
- Differentiate the safety profiles for BTK inhibitors as well as monitoring and management strategies to mitigate adverse effects.
- Analyze the cost drivers associated with the management of CLL and the value of evolving treatment approaches in lowering the cost of care and health care utilization.
Matthew Chui, PharmD, BCOP
Clinical Oncology Pharmacy Manager
University of Miami Health System
Sylvester Comphrensive Cancer Center
Miami, Florida
Timothy Mok, PharmD, BCPS, BCOP
Hematology Oncology Pharmacy Research Analyst
Kaiser Permanente
Oakland, California
Assistant Clinical Professor
UCSF School of Pharmacy
San Francisco, California
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-293-L01-P. The activity is available for CE credit through January 19, 2025.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty
Matthew Chui, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Consultant (advisory board): Lilly, AbbVie Inc
Timothy Mok, PharmD, BCPS, BCOP, has the following relevant financial relationship with a commercial interest to disclose:
Consultant: Pfizer Inc
The following contributors have no relevant financial relationships with commercial interests to disclose:
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms